Since sunitinib malate increases the levels of PD-1 and PD-L1 in the TME of tumor-bearing mice, its combined therapy with anti-PD-1 agents displays a significant reduction in tumors compared with either monotherapy, suggesting that it is reasonable to apply anti-PD-1 therapy after sunitinib malate treatment (Li W. et al., 2020). This evidence concerns the gene PDCD1 and neoplasm.